Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moberg Pharma ABMBGPF 49 3-Year EPS without NRI Growth Rate is 25.10% as of Jun. 2026, which is at its 10-year median of 25.10. GuruFocus rates MBGPF with a GF Score™ of 49/100 and a GF Value™ of $1.21 (Fairly Valued). Among 785 Drug Manufacturers companies, Moberg Pharma AB ranks better than 71.59% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 25.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 26.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Moberg Pharma AB was 61.90% per year. The lowest was -52.80% per year. And the median was 25.10% per year.
Moberg Pharma AB (OTCPK:MBGPF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Moberg Pharma AB 3-Year EPS without NRI Growth Rate Related Terms
MBGPF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's 3-Year EPS without NRI Growth Rate falls into.
Moberg Pharma AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 25.10% mean?
Moberg Pharma AB (MBGPF) has a 3-Year EPS without NRI Growth Rate of 25.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Moberg Pharma AB and its competitors. This is near median its historical median of 25.10. According to the industry distribution chart, Moberg Pharma AB ranks #223 out of 785 companies in the Drug Manufacturers industry, placing it in the top 28.4%.
Is Moberg Pharma AB's 3-Year EPS without NRI Growth Rate too high?
Moberg Pharma AB's current 3-Year EPS without NRI Growth Rate of 25.10% is near median its 10-year median of 25.10. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.70. Moberg Pharma AB's value of 25.10% is 158.8% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #223 out of 785 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Moberg Pharma AB has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #223 out of 785 companies for 3-Year EPS without NRI Growth Rate. This puts Moberg Pharma AB in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.70. Moberg Pharma AB's value of 25.10% is 158.8% above this benchmark. While the company's 10-year median is 25.10 vs. the industry median of 9.70, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.70, based on 785 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current 3-Year EPS without NRI Growth Rate of 25.10% is 158.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Moberg Pharma AB and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current 3-Year EPS without NRI Growth Rate is 25.10%, which is near median its own 10-year median of 25.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Moberg Pharma AB (MBGPF) is currently considered Fairly Valued. The stock's GF Value™ is $1.21, compared to a current price of $1.10 — trading 9.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 25.10%, which is near median its 10-year median of 25.10 and 158.8% above the Drug Manufacturers industry median of 9.70. Moberg Pharma AB's overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Moberg Pharma AB (MBGPF), the current 3-Year EPS without NRI Growth Rate is 25.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (MBGPF) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of $1.10 is trading 9.1% below its estimated GF Value™ of $1.21.
GuruFocus considers Moberg Pharma AB to be Fairly Valued.
Key valuation signals for MBGPF:
3-Year EPS without NRI Growth Rate: 25.10% (near median its 10-year median of 25.10)
GF Value™: $1.21 vs. price of $1.10 (9.1% below fair value)
Industry Position: 158.8% above the Drug Manufacturers median (#223 of 785)
No single metric tells the full story. See the MBGPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
49GF Score
Get the complete analysis for MBGPF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGPF has been successfully added to your 
